J Rheum Dis.  2014 Feb;21(1):1-3. 10.4078/jrd.2014.21.1.1.

Clinical Characteristics of Korean Rheumatoid Arthritis Patients with Indications for TNF-alpha Blocker

• Lee SI

• KMID: 2222981
• DOI: http://doi.org/10.4078/jrd.2014.21.1.1

Abstract

No abstract available.

MeSH Terms

Arthritis, Rheumatoid*
Humans
Tumor Necrosis Factor-alpha*
Tumor Necrosis Factor-alpha

Reference

References

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004; 350:2591–602.

2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365:2205–19.

3. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69:964–75.

4. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64:625–39.

5. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54:26–37.

6. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343:1586–93.

7. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol. 1995; 22:2208–13.

8. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year followup of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012; 379:1712–20.

9. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013; 369:307–18.

10. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73:492–509.

11. Son KM, Jung YO, Kim IJ, Kim BJ, Lee SY, Mun SY, et al. Clinical characteristics of Korean rheumatoid arthritis patients with indications for TNF-alpha blocker. J Rheum Dis. 2013; 20:356–60.

12. Song JS. Review of tumor necrosis factor inhibitors on rheumatoid arthritis. J Korean Rheum Assoc. 2007; 14:1–14.

13. Son KM, Jung DM, Kim YB, Han JS, Seo YI, Jung YO, et al. Comparison Korean National Health Insurance Reimbursement and Other Guidelines for TNF-alpha blocker in rheumatoid arthritis. J Rheum Dis. 2012; 19:334–40.